Evidence map›Paper›PMID 37584061›Full record

ArticlePreventive medicine reports2023

High coverage and adherence to dose intervals of the national school-based HPV vaccination program in Sweden during 2012-2019.

Jiangrong Wang, Eva Herweijer, Sara Nordqvist Kleppe, Susanne Hartwig, Christine Velicer, Carol Koro, Karin Sundström

Open access · goldAbstract read
In one paragraph

Article in Preventive medicine reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Jiangrong WangDepartment of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Eva HerweijerInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Sara Nordqvist KleppeDepartment of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Susanne HartwigMSD France, Lyon, France.
Christine VelicerMerck & Co., Inc., Rahway, NJ, USA.
Carol KoroMerck & Co., Inc., Rahway, NJ, USA.
Karin SundströmDepartment of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Karolinska Institutet · SEMerck & Co., Inc., Rahway, NJ, USA (United States) · USKarolinska University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Close monitoring of vaccination coverage is important for cervical cancer prevention efforts. The study aims to describe the HPV vaccination coverage by dose in girls eligible for HPV vaccination within Sweden's childhood immunization program and provide an estimate on dose timing compliance. Methods: Vaccination records between 2012 and March 2019 were obtained for girls born in 2000-2006 from the vaccination registers in Sweden. The mid-time population counts for the respective birth cohorts were taken as the denominator. Full-dose coverage and coverage with at least one dose of the vaccine were calculated within the two-dose and three-dose regimen, by region. Dose compliance was calculated within the two-dose regimen. Results: Vaccination coverage with at least one dose of the vaccine was >80% within birth cohorts 2001-2006. Full-dose coverage within a two-dose and three-dose regimen were 73.4% in birth cohorts 2004-2005, and 56.3% in birth cohorts 2000-2001, respectively. Little variation was observed in vaccination coverage between regions. Dose completion was 91.8%, and 72.8% in girls that initiated a two-dose and three-dose regimen, respectively. Among girls receiving a two-dose regimen, 93.0% received the second dose 6-12 months after dose one. Discussion: In conclusion, high levels of HPV vaccination coverage were observed with little variation between regions. Dose timing compliance was particularly high in the two-dose regimen. To fully benefit from the impact of HPV vaccination, it will be important to further push the vaccination coverage and reach the girls that do not or partially engage with HPV vaccination.

Indexed as

Dose complianceDose timingHPV vaccinationNationwideRegister-basedVaccination coverage

Identifiers

PMID37584061
PMCPMC10424256
OpenAlexW4385076781

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.